Skip to main content

Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis



Over the past decades, many studies focused on mesenchymal stem cells (MSCs) therapy for bone regeneration. Due to the efficiency of topical application has been widely dicussed and systemic application was also a feasible way for new bone formation, the aim of this study was to systematically review systemic therapy of MSCs for bone regeneration in pre-clinical studies.


The article search was conducted in PubMed and Embase databases. Original research articles that assessed potential effect of systemic application of MSCs for bone regeneration in vivo were selected and evaluated in this review, according to eligibility criteria. The efficacy of MSC systemic treatment was analyzed by random effects meta-analysis, and the outcomes were expressed in standard mean difference (SMD) and its 95% confidence interval. Subgroup analyses were conducted on animal species and gender, MSCs types, frequency and time of injection, and bone diseases.


Twenty-three articles were selected in this review, of which 21 were included in meta-analysis. The results showed that systemic therapy increased bone mineral density (SMD 3.02 [1.84, 4.20]), bone volume to tissue volume ratio (2.10 [1.16, 3.03]), and the percentage of new bone area (7.03 [2.10, 11.96]). Bone loss caused by systemic disease tended to produce a better response to systemic treatment (p=0.05 in BMD, p=0.03 in BV/TV).


This study concluded that systemic therapy of MSCs promotes bone regeneration in preclinical experiments. These results provided important information for the systemic application of MSCs as a potential application of bone formation in further animal experiments.


The problem of bone regeneration has always been a hot topic of research. In many cases, such as bone defect, fracture, osteoporosis, and osteonecrosis, bone regeneration is an urgent problem to be solved [1,2,3,4]. As we all know, bone undergoes continuous remodeling during life. Healthy bone remodeling includes both bone formation by osteoblasts and resorption by osteoclasts. An intricate balance between the activities of osteoblasts and osteoclasts determines the health of bone [5, 6]. Normally, small bone defects can be effectively repaired. However, in some cases, this balance may be disrupted, our body cannot maintain self-regenerate, and clinical treatment is needed [7, 8]. Therefore, further intervention in bone tissue engineering is required. For orthopedic and craniofacial surgeons, achieving complete and functional bone regeneration remains a major challenge.

A variety of techniques are used in the clinic for bone regeneration, such as bone grafting, distraction osteogenesis, and guided bone regeneration [9,10,11]. Several treatment methods have achieved clear therapeutic effects, especially autogenous bone grafts. Autogenous bone grafts is the gold standard for bone regeneration due to the osteoinductive, bone conductivity, and histocompatibility of autologous bone [12]. However, there are still several shortcomings of the gold standard such as extended recovery time, unpredictable absorption, and dependence of the donor’s bone quality and available bone size [13]. As the improvement of comprehension of bone tissue biology as well as current advances in the development of tissue engineering, mesenchymal stem cell (MSCs) therapy has become a hot topic in enhancing bone tissue reconstruction [8, 14, 15]. The main source of MSCs is bone marrow. In addition, they can also be isolated and identified from adipose tissue, peripheral blood, placenta, and other tissues [15,16,17]. MSCs play a vital role in bone formation [8], and bone is formed via endochondral and intramembranous ossification [18]. On the one hand, MSC-driven condensation occurs firstly, and then MSCs differentiate into chondrocytes during the process of formation of growth plates, which are replaced by new bone in longitudinal-endochondral bone growth. This type of healing mostly occurs in large bone defect with less mechanical stability, initiating the recruitment of MSCs from the periosteum, bone marrow, and circulation [19,20,21]. On the other hand, MSCs can also directly differentiate to osteoblasts in bone formation such as skull, facial bones, and pelvis, generating by intramembranous ossification without a cartilaginous template [22, 23]. This type of healing usually occurs in minimal bone defects and fractures within the bone metaphysis [21, 24]. However, in recent years, scholars have reported that in patients with osteoporosis, MSCs tend to differentiate into adipocytes rather than osteoblast, leading to disorders of bone formation [25].

Above all, majority of researches are devoted to application of MSCs in bone regeneration. Most researched treatments are local injection or local application of MSCs combined with scaffold [26,27,28]. However, local strategies still have some limitations, especially in systemic diseases such as multiple fractures and osteoporosis [29]. In these cases, systemic application is easier and more suitable for these patients. To the best of our knowledge, several systematic reviews have been published on the local application of MSCs for bone regeneration [30,31,32]. Nevertheless, no one focus on systemic application. This systematic review would help provide sufficient evidence to prove the therapeutic potential of systemic applying MSCs to regenerate animal bone tissues and clarify the limitations of existing studies.

Materials and methods

Eligibility criteria

Type of studies

All preclinical controlled animal model studies with systemic treatment of MSCs for bone regeneration were eligible for this review. Abstracts, reviews, letters, and PhD theses were excluded.

Type of participants

All kinds of animals were selected in this review irrespective of type, sex, and age. And any type of MSCs was considered in this systematic review such as bone marrow-derived mesenchymal stem cells (BMSCs), adipose-derived mesenchymal stem cells (ADSCs), gingiva-derived mesenchymal stem cells (GMSCs), dental pulp stem cells (DPSCs), and so on.

Type of intervention

Systemic application was compared with control treatment, including intravenous (IV) injection through tail vein or ear vein, intra-ventricular injection, bone marrow cavity’s injection, and so on. Studies utilizing only local application were excluded.

Outcome measures

To verify new bone formation, most researches adopted the measurement of bone volume (BV) to tissue volume (TV) ratio, bone mineral density (BMD), and percentage of new bone area. And the methods of measurement were comprised of histological analysis (such as haematoxylin and eosin) and radiographic evaluation (such as computed tomography [CT] scans and micro-CT).

Database search protocol

A comprehensive search of literature published up to July 2020 was performed in electronic databases PubMed and Embase. Four components were involved in the search strategy: bone regeneration, MSCs, systematic application, and animals (see Supplementary Table S1 for complete search strategy, Additional File 1).

Study screening

For selection of literatures, two independent reviewers screened the titles and abstracts of literatures independently according to the following eligibility criteria: bone regeneration, in vivo animal studies, original paper, and systemic therapy. Full texts of eligible publications were obtained for further independent evaluation. Any disagreement was solved by discussion or consultation with a third reviewer. Besides, reviews recorded reasons for each rejecting study. All of the progress of screening was performed in Rayyan, the systematic reviews web app (

Data extraction process

Data were extracted independently by two reviewers, with disagreements resolved by discussion with a third reviewer. Data was extracted from the full texts of included literatures on: author(s), year, species, age, sex of animals, number of animals per group, animal model, type of MSCs, cell passage number, number of cells, number of cells/kg, the way of administration, application protocol of MSCs (time, frequency of injection), treatment duration, quantification of new bone, combination treatment, and cellular fate of MSCs.

Quality assessment and risk of bias

Quality assessment of selected articles was performed independently by two reviewers, and the names of the authors, institutions, and journal titles were blinded. Systematic Review Centre for Laboratory animal Experimentation (SYRCLE) Risk of bias (RoB) tool for animal studies was modified and used to performed RoB assessment [33], which was judged as “high,” “low,” or “unclear.” Two questions were added to overcome the problem of scoring excessive “unclear RoB” due to poor reporting details of the include experiments: “1) was it stated that the experiment was randomized at any level?2) was it stated that the experiment was blinded at any level?” [34, 35]. Any disagreement between the reviewers was resolved by discussion and consensus.

Data synthesis and statistical analysis

Data were analyzed using Review Manager. The primary outcomes BMD between experimental and control groups was performed by meta-analysis, calculating the standardized mean difference (SMD). Besides, BV/TV and percentage of new bone area were also analyzed in this review. If one reference studied with different treatment duration, we just analyzed the longest follow-up time point. I2 statistic assessed statistical heterogeneity among included studies, and a random effects model was used if high heterogeneity existed. Forest plots were selected to graphically display effect sizes and their confidence intervals (CI). Subgroup analysis and investigation of heterogeneity were used to explore possible sources of heterogeneity. And subgroup analysis was carried out based on following factors: animal species and gender, the type of cells, frequency and time of injection, and bone diseases. But when we analyzed the gender subgroup, studies with animal models of ovariectomy (OVX)-induced bone loss were excluded because of the limited gender. In addition, it was performed only if it contains at least four independent experiments.


Selection of the studies

After duplication in Endnote, the initial search in the PubMed and Embase databases resulted in 3579 papers. After initial screening based on titles and abstracts in Rayyan, 110 publications were obtained for analyzation of full text. Eventually, 23 articles were included after full-text screening [36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58], and 21 studies were selected for meta-analysis (Fig. 1). Two trials [43, 58] were withheld from meta-analysis due to the quantification of new bone was not involved in BV/TV, BMD, or the percentage of newly formed bone.

Fig. 1

Flowchart for study screening and selection

Study characteristics of selected papers are displayed in Table 1. Four different animal species were used: most commonly used species was mice (15 studies), followed by rat (5 studies), swine (2 studies), and dog (1 study). Male and female animals were approximately equally used in these researches and 2 papers did not mention the gender of animals. Various animal models of bone disease were involved, including different sizes of bone defects (5 studies), different types of bone fractures (9 studies), and different causes of bone loss including osteoporosis, ovariectomy, and osteonecrosis (9 studies). BMSCs were evaluated for bone regeneration in most studies (16 studies), and other five different cell types were also reported, including DSCs (1 study), GMSCs (1 study), ADSCs (2 studies), uterine stem cell-derived osteoprogenitor cells (1 study), umbilical cord blood (UCB)-MSCs (1 study), and MSCs of uncertain origin (1 study). Moreover, both passage number and cell dosing varied greatly across the researches, ranging from passage 1 to passage 8, from 3 × 104 to 4 × 109 cells. Generally, IV injection is the most frequently applied method for systemic therapy (20 studies), and other studies also used bone marrow cavity’s injection (1 study) and intra-ventricular injection (2 studies). Most researches used a single injection (18 studies), and other researches used two (2 studies), four (1 study), five (1 study), or eight (1 study) injections. In the majority of cases, MSCs were injected after surgery (16 studies) or during surgery (5 studies), and only one study used MSC injection before the femoral fracture model was constructed. Moreover, the heterogeneity between the combination treatments was discovered among articles (8 studies), and only LLP2A-Alendronate was mentioned twice.

Table 1 Summary of study characteristics in animal model

Risk of bias

Assessment of risk of bias for included studies was assessed and listed in Fig. 2. 56.5% of these studies reported randomization of the group designing. But none of these articles described the methods of randomization and the method used to conceal the allocation sequence, so the allocation sequence inadequately generated and applied. Almost half of the included studies described that all groups were in the same conditions at the start of experiments. And only 17.4% of studies randomly housed the animals during the experiment. Moreover, all studies were defined as low risk of bias of “random outcome assessment” for performance deviation items since the effect of experiment groups and control groups were evaluated at the same time. Meanwhile, 73.9% of experiments failed to mention that the experiment was blinded even 91.3% of studies without blinding of housing procedures and operators. In final analyzation of outcomes, 21.7% of studies reported outcome assessors were blinded to different groups and 21.8% of studies did not report the incomplete outcome data. In addition, the majority of studies scored at low risk in the bias of other problems. In conclusion, selection bias and performance bias were scored at unclear risk, but detection bias and attrition bias were almost scored at low risk.

Fig. 2

Risk of bias


Twenty-one researches were included and three main outcomes were selected in this meta-analysis, including BMD (12 studies), BV/TV (10 studies), and percentage of new bone area (4 studies).

The main parameter: BMD

BMD has always been an important index in evaluating bone regeneration [59]. The twelve identified references involved 348 animals (178 treated groups and 170 control groups) to evaluate BMD of systemic treatment of MSCs on new bone regeneration. Five experiments showed insignificant differences. Only one experiment displayed a negative effect on treated group and eleven experiments represented a positive effect on treated group compared with the corresponding control groups. Overall, there was a statistically significant beneficial effect of systemic treatment on new bone regeneration, as shown by the global estimate SMD and its 95% CIs (3.02 [1.84, 4.20]). But heterogeneity testing showed that I2=92%, indicating high heterogeneity (Fig. 3).

Fig. 3

The forest plot: the effects of MSCs therapy on BMD, compared with controls. 95% CI, 95% confidence interval

Subgroup analysis was carried out according to different animal species and gender, cell types, frequency and time of injection, and bone diseases. All analysis showed positive effect on systemic treatment except rat subgroup. And the analysis showed that the species of animal (p<0.0001) is the significant predictor of enhancing BMD, although the heterogeneity among studies was significant high (Table 2).

Table 2 BMD: stratified analysis of MSC-treated vs. control


The nine identified references involved 196 animals (98 treated groups and 98 control groups) to evaluate BV/TV. Five experiments presented insignificant differences, while eight experiments showed positive effect on treated group compared with control group. Overall, there was a statistically significant beneficial effect of systemic treatment on BV/TV, as shown by the global estimate SMD and its 95% CIs (2.10 [1.16, 3.03]). But heterogeneity testing still showed that I2=78%, indicating high heterogeneity (Fig. 4).

Fig. 4

The forest plot: the effects of MSCs therapy on BV/TV, compared with controls. 95% CI, 95% confidence interval

Subgroup analysis showed a beneficial effect of all subgroups. The subgroups of rat, other types of MSCs, multiple injections, injection while modeling, and female were not performed because the analysis required at least four independent comparisons. In addition, the analysis showed that bone diseases (p=0.03) are the significant predictor of enhancing BV/TV, although the heterogeneity among studies was significantly high (Table 3).

Table 3 BV/TV: stratified analysis of MSC-treated vs. control

New bone formation

The three identified references involved 84 animals (43 treated groups and 41 control groups) to evaluate the percentage of new bone area. Only one experiment found a statistically insignificant effect on new bone formation. Overall analysis showed that systemic strategies enhanced new bone formation, as shown by the global estimate SMD and its 95% CIs (7.03 [2.10, 11.96]). But heterogeneity testing showed that I2=93%, indicating the high heterogeneity (Fig. 5).

Fig. 5

The forest plot: the effects of MSCs therapy on the percentage of new bone area, compared with controls. 95% CI, 95% confidence interval


Twenty-three published animal researches with systemic treatment of MSCs were analyzed to investigate the effect of bone regeneration. The following is a brief summary of these results: (1) systemic application of MSCs promotes bone regeneration which was measured with BMD, BV/TV, or the percentage of new bone area. (2) Bone loss caused by systemic disease such as osteoporosis and osteonecrosis tended to produce a better response to systemic treatment. Although the difference was not statistically significant (p=0.05) in BMD, we believe that a statistically significant difference would be observed with more studies.

The meta-analysis results strengthened the evidence supporting systemic application of MSCs in bone regeneration. Only one study compared the efficacy of local and systemic treatments: Huang et al. [51] used femoral fracture models of mice to demonstrate that systemic and local application of MSCs promoted fracture healing equally by direct differentiate into osteoblasts. As we mentioned before, systemic bone disease has a better effect when using systemic injection. And local application is more suitable for bone fractures and bone defects.

Nowadays, the process of IV of MSCs in vivo was studied. MSCs are most initially trapped in lung microvasculature and rapidly phagocytosed by lung resident tissue macrophages. Then, MSCs may be recirculated and home to different organs, mostly liver due to the high circulating blood volume. At last, a small subset may redistribute to sites of injury or damage [60, 61]. However, intra-ventricular, which is a more invasive method, could deliver more MSCs to target sites. Besides, other methods of systemic administration include intra-arterial injection and intra-peritoneal administration but they were mostly used in stroke and cancer respectively [62]. In this systematic review, most of the included studies showed that MSCs could home to the site of bone defects or bone marrow, although some of them confirmed that most of the cells trapped in lungs, liver, kidneys, lymph nodes, and spleen (Table 1).

To date, the mechanism of stem cell transplantation therapy is based on the following: (1) MSCs still have the ability of homing to the injury site and differentiation into osteoblasts and chondrocytes directly although the number of these MSCs is limited [63,64,65]. (2) The paracrine effects of MSCs was secreting related factors such as cytokines, bone growth factors, chemokines to simulate angiogenesis and osteogenesis and recruiting host cells to the target sites [66, 67]. (3) It has been proved that MSCs have highly immunosuppressive functions which do not depend on the direct contact with immune cells, but on the recognition of MSCs by monocytic cells and evoking phagocytosis of macrophages [68]. In addition, MSCs can modulate the inflammatory micro-environment at the defect area and decrease the levels of interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) [69]. Except non-specific immune suppressive effect, MSCs also has an effect on the specific immune system. On the one hand, MSCs can inhibit a series of activities of T cells, including the survival, activation, differentiation of T cell subsets, and even transformation of functional regulatory T (Treg) cells [70]. On the other hand, MSCs can also suppress several key steps of B cell-mediated immune responses, such as activation, proliferation, differentiation, and chemotactic responses [71]. As for systemic administration, many researchers who study the diseases of bone defect and bone fracture often only focus on the effect of MSCs for bone formation without explaining the specific mechanism [37, 48, 49]. Some of them verified MSCs could be recruited and home to defect sites to enhance new bone formation. Wu, Li, and Wang emphasized a key role of stromal cell-derived Factor-1/chemokine receptor 4 interaction in the migration of MSCs to the defect region [36, 38, 54]. Furthermore, more researches focus on the indirect effect of MSCs. The study by Yao et al. [52] reported that MSCs could alter the tissue microenvironment via paracrine signaling, secretion of chemokines, as well as angiogenic and anti-inflammatory factors. Wang et al. also concluded that MSCs could promote osteogenesis and bone calcification through the secretion of bone growth factors such as bone morphogenetic protein 2 and transforming growth factor-β1 [54]. Besides, Kumar et al. found that the paracrine effects of MSCs were essential to promote osteogenesis by inducing the expression of growth factors and cytokines in the local micro-environment and recruiting endogenous progenitor cells [45]. For immunosuppressive function, Li et al. reported that systemic MSC transplantation could suppress IL-17 and γδT cells and increase the level of Tregs in peripheral blood [57]. Sui et al. also inferred that systemically infused MSCs reduced total T-cell population and suppressed inflammation [41]. But these studies did not render unifying conclusions, so the mechanisms of systemic transplantation remain to be further elucidated.

In addition, some of the included studies mentioned combination treatment in this systematic review. Nowadays, a lot of researches have studied the combination treatment with MSCs in local application for bone regeneration. Compared with the local application of MSCs alone, the combined application of MSCs with protein molecules and scaffolds is usually more conducive to promoting bone regeneration [72, 73]. However, combination treatment in systemic applying of MSCs for bone engineering is a less explored area of research. Most of researches focus on protein molecule or ultrasound which could promote the effects on the angiogenesis efficiency of MSCs, such as erythropoietin (EPO) [38], LIPUS [49], and PTH1-34 [55]; some combination treatments could have a direct effect on osteogenesis, such as IGF-I [58] and BMP2 [45]; some protein molecules could increase the homing of transplanted MSCs to bone, such as LLP2A-Ale [43, 52] and PTH1-34 [55]. Besides, hypoxic was detected to be an effective way to improve the survival rate, recruitment, and osteogenesis of MSCs in transplantation, and its effects were mainly achieved through the SDF-1/CXCR4 axis [36]. Further researches are needed to evaluate the combination therapy of MSCs in order to discover more effective potential bone regeneration treatments.

However, we acknowledge some limitations regarding this systematic review. First, the assessment of risk of bias revealed that the body of the evidence was generally at a low quality, because RoB was scored “unclear” in the selected studies. As shown in Fig. 2, few articles reported the most important methods to avoid bias, such as randomization and blinding. For example, neither the methods of randomization nor whether the outcome assessment was blinded were reported in these included studies. This will increase the substantial risk of misunderstanding the effect of systemic therapy of MSCs on bone regeneration. Second, the included researches were differed from animal species and sex, bone disease model, the number and types of cells, the healing time, and so on. Therefore, high statistical heterogeneity was found in this meta-analysis. Random effects model was used to account for these results, and subgroup analyses (animal species, sex, bone disease and cell types) were performed in these analyses, but failed to reduce the heterogeneity. So, more comprehensive studies are needed to further evaluate these results. Third, due to the low quality of evidence, the results of this systematic review should be interpreted with caution. In the process of this systematic review, we have tried to reduce bias in the following ways: independent screening, data extraction, independent evaluation of results, and risk of bias evaluation.

Nowadays, few complete clinical trials for bone regeneration with systemic treatment has been reported until now while two studies were submitted in the web of clinical trials. Both of them focus on osteoporosis patients while allogenic MSC form umbilical cord and fucosylated BMSCs were used respectively in these studies. However, there are some problems still need to be discussed before adapting the systemic treatment of bone regeneration to clinical application. First of all, the type of MSCs used is one of the most important issues. BMSCs are the most commonly used in this systematic review, and they are also widely used for bone regeneration purposes. Because of the limited number of studies using other types of MSCs, we designed the studies grouped by BMSCs and other types of MSCs. And under the subgroup analysis, BMSCs displayed a favorable effect on bone regeneration, although there is no significant difference between the two subgroups. But this result should be taken with caution because of the high heterogeneity and small amounts of studies. Second, the passage number of MSCs used in treatment requires an objective measurement standard. MSCs ranging from passage 1 to passage 8 were conducted in this systematic review. Because the low frequency of MSCs we can acquired from the donor tissue, in vitro expansion is necessary for clinical use [74]. MSCs with a high number of passages enter senescence and begin to lose their stem cell characteristics such as proliferation and differentiation capabilities [75, 76]. As a result, the passage number is crucial to the final outcomes, whereas nearly half of the included studies ignore this important information. Thus it is strongly recommended that the passage number of MSCs should be clarified in future researches. Besides, the optimal cell dose is still unclear. MSCs with a concentration ranging from 6.25 × 104/kg to 4 × 108/kg were used in this systematic review; none of them studies the effect of different concentrations on bone regeneration. In this review, 15 included studies neglected to record body weight and only recorded the total number of transplanted cells. For the moment, cell dosing in clinical studies is based on the weight of patients, generally 1 × 105/kg, not more than 1.2 × 106/kg [61]. Therefore, it is necessary to display the weight of animals to provide references for clinical application. In addition, the cell dosing of different animals varied greatly. Both Li and Wilson et al. [48, 57] used swine models and the cell dosing are 2.5–3.3×104/kg and 6.25–8.3×104/kg respectively, while others who chosen rodents as experimental subjects are ranging from 1 × 105/kg to 2 × 107/kg. As a result, further studies should discuss the optimal dosing of MSCs in different species because the improper dosing may cause different responses. Moreover, most animal models selected in these systematic reviews are rodents (20 of 23 studies). This result may be due to the fact that rodents are easy to get and house, which tend to be selected to preliminary screenings. However, they have many anatomical and physiological differences with humans. And large animals, such as swine, should be used for validation of new therapy in the last phase, since large animals have more similarities with humans [77].

The time and frequency of injections are also issues that we need to pay attention to. Most of the existing studies use a single injection, but we found that multiple injections may have better outcomes in the evaluation of BMD, though meta-analysis has not been performed due to too few studies. Therefore, comparing the effects of single injection and multiple injections on bone regeneration is a future research direction. As for the injection time point, when we observe the preventive effect of bone loss, injection was normally conducted before or at the same time as the operation, while injection after surgery showed a therapeutic effect. However, most studies focus on the therapeutic role of MSCs in bone regeneration. Therefore, future researches may also be extended to the systemic therapy effect of MSCs to prevent bone loss, which is a promising treatment strategy to prevent osteoporosis caused by hormone changes or aging.

In summary, before clinical application, more researches on the systemic application of MSCs for bone regeneration should be carried out. Not only should we pay attention to application protocol of MSCs, but also explore how to transform the models into large animals.


Based on the data of this meta-analysis, systemic application of MSCs promote bone regeneration compared with control groups, by assessing the treatment outcomes including BMD, BV/TV, or the percentage of new bone area. The role of MSCs in bone formation may include homing and differentiation, angiogenesis, inflammation, and immune response. However, due to the limitations inherent in the design of most included researches in this systematic review, there is still a long way to go before systemic treatment of MSCs for bone regeneration can be applied to the clinic. The results of this systematic review provide some certain reference for future experiments.

Availability of data and materials

All supporting data are included in the article and its additional files.



Mesenchymal stem cells


Standard mean difference


Bone marrow-derived mesenchymal stem cells


Adipose-derived mesenchymal stem cells


Gingiva-derived mesenchymal stem cells


Dental pulp stem cells




Bone mineral density


Computed tomography


Systematic Review Centre for Laboratory animal Experimentation


Risk of bias


Confidence intervals




Umbilical cord blood

IL :



Tumor necrosis factor-α


Regulatory T


  1. 1.

    Oryan A, Alidadi S. Reconstruction of radial bone defect in rat by calcium silicate biomaterials. Life Sci. 2018;201:45–53.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Wang M, Park S, Nam Y, Nielsen J, Low SA, Srinivasarao M, et al. Bone-fracture-targeted dasatinib-oligoaspartic acid conjugate potently accelerates fracture repair. Bioconjug Chem. 2018;29(11):3800–9.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Qaseem A, Forciea MA, McLean RM, Denberg TD. Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med. 2017;166(11):818–39.

    Article  PubMed  Google Scholar 

  4. 4.

    Kishimoto H, Noguchi K, Takaoka K. Novel insight into the management of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Jpn Dent Sci Rev. 2019;55(1):95–102.

    Article  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Hattner R, Epker BN, Frost HM. Suggested sequential mode of control of changes in cell behaviour in adult bone remodelling. Nature. 1965;206(983):489–90.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Sims NA, Martin TJ. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep. 2014;3:481.

    PubMed  PubMed Central  Google Scholar 

  7. 7.

    Loi F, Córdova LA, Pajarinen J, Lin TH, Yao Z, Goodman SB. Inflammation, fracture and bone repair. Bone. 2016;86:119–30.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Su P, Tian Y, Yang C, Ma X, Wang X, Pei J, et al. Mesenchymal stem cell migration during bone formation and bone diseases therapy. Int J Mol Sci. 2018;19(8):2343.

    CAS  Article  PubMed Central  Google Scholar 

  9. 9.

    Grassi FR, Grassi R, Rapone B, Alemanno G, Balena A, Kalemaj Z. Dimensional changes of buccal bone plate in immediate implants inserted through open flap, open flap and bone grafting and flapless techniques: a cone-beam computed tomography randomized controlled clinical trial. Clin Oral Implants Res. 2019;30(12):1155–64.

    Article  PubMed  Google Scholar 

  10. 10.

    Hopper RA, Kapadia H, Susarla S, Bly R, Johnson K. Counterclockwise craniofacial distraction osteogenesis for tracheostomy-dependent children with Treacher Collins syndrome. Plast Reconstr Surg. 2018;142(2):447–57.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Cai Y, Guo J, Chen C, Yao C, Chung SM, Yao J, et al. Silk fibroin membrane used for guided bone tissue regeneration. Mater Sci Eng C Mater Biol Appl. 2017;70(Pt 1):148–54.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Raghoebar GM, Liem RS, Bos RR, van der Wal JE, Vissink A. Resorbable screws for fixation of autologous bone grafts. Clin Oral Implants Res. 2006;17(3):288–93.

    Article  PubMed  Google Scholar 

  13. 13.

    Dimitriou R, Mataliotakis GI, Angoules AG, Kanakaris NK, Giannoudis PV. Complications following autologous bone graft harvesting from the iliac crest and using the RIA: a systematic review. Injury. 2011;42(Suppl 2):S3–15.

    Article  PubMed  Google Scholar 

  14. 14.

    Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface. 2011;8(55):153–70.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Liu Y, Yang R, Shi S. Systemic infusion of mesenchymal stem cells improves cell-based bone regeneration via upregulation of regulatory T cells. Tissue Eng Part A. 2015;21(3):498–509.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Puglisi MA, Saulnier N, Piscaglia AC, Tondi P, Agnes S, Gasbarrini A. Adipose tissue-derived mesenchymal stem cells and hepatic differentiation: old concepts and future perspectives. Eur Rev Med Pharmacol Sci. 2011;15(4):355–64.

    CAS  PubMed  Google Scholar 

  17. 17.

    Jin HJ, Nam HY, Bae YK, Kim SY, Im IR, Oh W, et al. GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells. Cell Mol Life Sci. 2010;67(11):1845–58.

    CAS  Article  PubMed  Google Scholar 

  18. 18.

    Takigawa M. CCN2: a master regulator of the genesis of bone and cartilage. J Cell Commun Signal. 2013;7(3):191–201.

    Article  PubMed  PubMed Central  Google Scholar 

  19. 19.

    Hirota K, Yasoda A, Kanai Y, Ueda Y, Yamauchi I, Yamashita T, et al. Live imaging analysis of the growth plate in a murine long bone explanted culture system. Sci Rep. 2018;8(1):10332.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Wilsman NJ, Farnum CE, Leiferman EM, Fry M, Barreto C. Differential growth by growth plates as a function of multiple parameters of chondrocytic kinetics. J Orthop Res. 1996;14(6):927–36.

    CAS  Article  PubMed  Google Scholar 

  21. 21.

    Bastian O, Pillay J, Alblas J, Leenen L, Koenderman L, Blokhuis T. Systemic inflammation and fracture healing. J Leukoc Biol. 2011;89(5):669–73.

    CAS  Article  Google Scholar 

  22. 22.

    Berendsen AD, Olsen BR. Bone development. Bone. 2015;80:14–8.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. 23.

    Percival CJ, Richtsmeier JT. Angiogenesis and intramembranous osteogenesis. Dev Dyn. 2013;242(8):909–22.

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Pajarinen J, Lin T, Gibon E, Kohno Y, Maruyama M, Nathan K, et al. Mesenchymal stem cell-macrophage crosstalk and bone healing. Biomaterials. 2019;196:80–9.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Hu L, Yin C, Zhao F, Ali A, Ma J, Qian A. Mesenchymal stem cells: cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment. Int J Mol Sci. 2018;19(2):360.

    CAS  Article  PubMed Central  Google Scholar 

  26. 26.

    Wu Y, Zhang C, Wu J, Han Y, Wu C. Angiogenesis and bone regeneration by mesenchymal stem cell transplantation with danshen in a rabbit model of avascular necrotic femoral head. Exp Ther Med. 2019;18(1):163–71.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Choi Y, Yoon DS, Lee KM, Choi SM, Lee MH, Park KH, et al. Enhancement of mesenchymal stem cell-driven bone regeneration by resveratrol-mediated SOX2 regulation. Aging Dis. 2019;10(4):818–33.

    Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Basile M, Marchegiani F, Novak S, Kalajzic I, Di Pietro R. Human amniotic fluid stem cells attract osteoprogenitor cells in bone healing. J Cell Physiol. 2020;235(5):4643–54.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Dimitriou R, Jones E, McGonagle D, Giannoudis PV. Bone regeneration: current concepts and future directions. BMC Med. 2011;9(1):66.

    Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Sun K, Zhou Z, Ju X, Zhou Y, Lan J, Chen D, et al. Combined transplantation of mesenchymal stem cells and endothelial progenitor cells for tissue engineering: a systematic review and meta-analysis. Stem Cell Res Ther. 2016;7(1):151.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Ambikaipalan A, Wong JM, Khan WS. Preclinical and clinical studies on the use of stem cells for bone repair: a systematic review. Curr Stem Cell Res Ther. 2013;8(3):210–6.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Liao Y, Zhang XL, Li L, Shen FM, Zhong MK. Stem cell therapy for bone repair: a systematic review and meta-analysis of preclinical studies with large animal models. Br J Clin Pharmacol. 2014;78(4):718–26.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. 33.

    Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1):43.

    Article  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Yan XZ, Yang F, Jansen JA, de Vries RB, van den Beucken JJ. Cell-based approaches in periodontal regeneration: a systematic review and meta-analysis of periodontal defect models in animal experimental work. Tissue Eng B Rev. 2015;21(5):411–26.

    Article  Google Scholar 

  35. 35.

    Wang B, Shao J, Fu J, Jansen JA, Walboomers XF, Hooijmans CR, et al. Topical host-modulating therapy for periodontal regeneration: a systematic review and meta-analysis. Tissue Eng B Rev. 2019;25(6):526–43.

    Article  Google Scholar 

  36. 36.

    Wu Y, Huang F, Zhou X, Yu S, Tang Q, Li S, et al. Hypoxic preconditioning enhances dental pulp stem cell therapy for infection-caused bone destruction. Tissue Eng Part A. 2016;22(19-20):1191–203.

    CAS  Article  PubMed  Google Scholar 

  37. 37.

    Liu X, Liao X, Luo E, Chen W, Bao C, Xu HHK. Mesenchymal stem cells systemically injected into femoral marrow of dogs home to mandibular defects to enhance new bone formation. Tissue Eng A. 2014;20(3-4):883–92.

    CAS  Article  Google Scholar 

  38. 38.

    Li J, Huang Z, Li B, Zhang Z, Liu L. Mobilization of transplanted bone marrow mesenchymal stem cells by erythropoietin facilitates the reconstruction of segmental bone defect. Stem Cells Int. 2019;2019:5750967.

    PubMed  PubMed Central  Google Scholar 

  39. 39.

    Xu QC, Wang ZG, Ji QX, Yu XB, Xu XY, Yuan CQ, et al. Systemically transplanted human gingiva-derived mesenchymal stem cells contributing to bone tissue regeneration. Int J Clin Exp Pathol. 2014;7(8):4922–9.

    PubMed  PubMed Central  Google Scholar 

  40. 40.

    Sui B, Hu C, Zhang X, Zhao P, He T, Zhou C, et al. Allogeneic mesenchymal stem cell therapy promotes osteoblastogenesis and prevents glucocorticoid-induced osteoporosis. Stem Cells Transl Med. 2016;5(9):1238–46.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Sui BD, Chen J, Zhang XY, He T, Zhao P, Zheng CX, et al. Gender-independent efficacy of mesenchymal stem cell therapy in sex hormone-deficient bone loss via immunosuppression and resident stem cell recovery. Exp Mol Med. 2018;50(12):1–14.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Wang Z, Wang D, Liu Y, Liu D, Ren Y, Liu Z, et al. Mesenchymal stem cell in mice uterine and its therapeutic effect on osteoporosis. Rejuvenation Res. 2020;24(2):139–50.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Yao W, Guan M, Jia J, Dai W, Lay YAE, Amugongo S, et al. Reversing bone loss by directing mesenchymal stem cells to bone. Stem Cells. 2013;31(9):2003–14.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Kiernan J, Hu S, Grynpas MD, Davies JE, Stanford WL. Systemic mesenchymal stromal cell transplantation prevents functional bone loss in a mouse model of age-related osteoporosis. Stem Cells Transl Med. 2016;5(5):683–93.

    Article  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Kumar S, Nagy TR, Ponnazhagan S. Therapeutic potential of genetically modified adult stem cells for osteopenia. Gene Ther. 2010;17(1):105–16.

    CAS  Article  PubMed  Google Scholar 

  46. 46.

    An JH, Park H, Song JA, Ki KH, Yang J-Y, Choi HJ, et al. Transplantation of human umbilical cord blood-derived mesenchymal stem cells or their conditioned medium prevents bone loss in ovariectomized nude mice. Tissue Eng A. 2013;19(5-6):685–96.

    CAS  Article  Google Scholar 

  47. 47.

    Chen GH, Huang GZ, Lin H, Wu HJ, Chen H. Bone marrow mesenchymal stem cell transplantation increases bone mineral density of an ovariectomized rat model of osteoporosis. Zhongguo Zuzhi Gongcheng Yanjiu. 2017;21(1):49–53.

    Google Scholar 

  48. 48.

    Wilson SM, Goldwasser MS, Clark SG, Monaco E, Bionaz M, Hurley WL, et al. Adipose-derived mesenchymal stem cells enhance healing of mandibular defects in the ramus of swine. J Oral Maxillofac Surg. 2012;70(3):e193–203.

    Article  PubMed  Google Scholar 

  49. 49.

    Cheung WH, Chin WC, Wei FY, Li G, Leung KS. Applications of exogenous mesenchymal stem cells and low intensity pulsed ultrasound enhance fracture healing in rat model. Ultrasound Med Biol. 2013;39(1):117–25.

    Article  PubMed  Google Scholar 

  50. 50.

    Weaver AS, Su YP, Begun DL, Miller JD, Alford AI, Goldstein SA. The effects of axial displacement on fracture callus morphology and MSC homing depend on the timing of application. Bone. 2010;47(1):41–8.

    Article  PubMed  PubMed Central  Google Scholar 

  51. 51.

    Huang S, Xu L, Sun Y, Zhang Y, Li G. The fate of systemically administrated allogeneic mesenchymal stem cells in mouse femoral fracture healing. Stem Cell Res Ther. 2015;6(1):206.

    Article  PubMed  PubMed Central  Google Scholar 

  52. 52.

    Yao W, Lay YE, Kot A, Liu R, Zhang H, Chen H, et al. Improved mobilization of exogenous mesenchymal stem cells to bone for fracture healing and sex difference. Stem Cells. 2016;34(10):2587–600.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  53. 53.

    Tanrıverdi AK, Polat O, Elçin AE, Ahlat O, Gürman G, Günalp M, et al. Mesenchymal stem cell transplantation in polytrauma: evaluation of bone and liver healing response in an experimental rat model. Eur J Trauma Emerg Surg. 2020;46(1):53–64.

    Article  PubMed  Google Scholar 

  54. 54.

    Wang X, Wang C, Gou W, Xu X, Wang Y, Wang A, et al. The optimal time to inject bone mesenchymal stem cells for fracture healing in a murine model. Stem Cell Res Ther. 2018;9(1):272.

  55. 55.

    Jiang X, Xu C, Shi H, Cheng Q. PTH1-34 improves bone healing by promoting angiogenesis and facilitating MSCs migration and differentiation in a stabilized fracture mouse model. PLoS One. 2019;14(12):e0226163.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Rapp AE, Bindl R, Heilmann A, Erbacher A, Müller I, Brenner RE, et al. Systemic mesenchymal stem cell administration enhances bone formation in fracture repair but not load-induced bone formation. Eur Cell Mater. 2015;29:22–34.

    CAS  Article  PubMed  Google Scholar 

  57. 57.

    Li Y, Xu J, Mao L, Liu Y, Gao R, Zheng Z, et al. Allogeneic mesenchymal stem cell therapy for bisphosphonate-related jaw osteonecrosis in swine. Stem Cells Dev. 2013;22(14):2047–56.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  58. 58.

    Myers TJ, Yan Y, Granero-Molto F, Weis JA, Longobardi L, Li T, et al. Systemically delivered insulin-like growth factor-I enhances mesenchymal stem cell-dependent fracture healing. Growth Factors. 2012;30(4):230–41.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Jha S, Chapman M, Roszko K. When low bone mineral density and fractures is not osteoporosis. Curr Osteoporos Rep. 2019;17(5):324–32.

    Article  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Ito H. Chemokines in mesenchymal stem cell therapy for bone repair: a novel concept of recruiting mesenchymal stem cells and the possible cell sources. Mod Rheumatol. 2011;21(2):113–21.

    CAS  Article  PubMed  Google Scholar 

  61. 61.

    Yu D-A, Han J, Kim B-S. Stimulation of chondrogenic differentiation of mesenchymal stem cells. Int J Stem Cells. 2012;5(1):16–22.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science (New York, NY). 1999;284(5411):143–7.

    CAS  Article  Google Scholar 

  63. 63.

    Fu X, Liu G, Halim A, Ju Y, Luo Q, Song AG. Mesenchymal stem cell migration and tissue repair. Cells. 2019;8(8):784.

    CAS  Article  PubMed Central  Google Scholar 

  64. 64.

    Ren G, Chen X, Dong F, Li W, Ren X, Zhang Y, et al. Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med. 2012;1(1):51–8.

    CAS  Article  PubMed  Google Scholar 

  65. 65.

    Li ZY, Wang CQ, Lu G, Pan XY, Xu KL. Effects of bone marrow mesenchymal stem cells on hematopoietic recovery and acute graft-versus-host disease in murine allogeneic umbilical cord blood transplantation model. Cell Biochem Biophys. 2014;70(1):115–22.

    CAS  Article  PubMed  Google Scholar 

  66. 66.

    Galipeau J, Sensébé L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824–33.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  67. 67.

    Luo Y, Wang B, Liu J, Ma F, Luo D, Zheng Z, et al. Ginsenoside RG1 enhances the paracrine effects of bone marrow-derived mesenchymal stem cells on radiation induced intestinal injury. Aging. 2020;13(1):1132–52.

    Article  PubMed  PubMed Central  Google Scholar 

  68. 68.

    Liu H, Li D, Zhang Y, Li M. Inflammation, mesenchymal stem cells and bone regeneration. Histochem Cell Biol. 2018;149(4):393–404.

    CAS  Article  PubMed  Google Scholar 

  69. 69.

    Cao W, Cao K, Cao J, Wang Y, Shi Y. Mesenchymal stem cells and adaptive immune responses. Immunol Lett. 2015;168(2):147–53.

    CAS  Article  PubMed  Google Scholar 

  70. 70.

    Rahimzadeh A, Mirakabad FS, Movassaghpour A, Shamsasenjan K, Kariminekoo S, Talebi M, et al. Biotechnological and biomedical applications of mesenchymal stem cells as a therapeutic system. Artif Cells Nanomed Biotechnol. 2016;44(2):559–70.

    CAS  Article  PubMed  Google Scholar 

  71. 71.

    Carreras-Planella L, Monguió-Tortajada M, Borràs FE, Franquesa M. Immunomodulatory effect of MSC on B cells is independent of secreted extracellular vesicles. Front Immunol. 2019;10:1288.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  72. 72.

    Xia Y, Sun J, Zhao L, Zhang F, Liang XJ, Guo Y, et al. Magnetic field and nano-scaffolds with stem cells to enhance bone regeneration. Biomaterials. 2018;183:151–70.

    CAS  Article  PubMed  Google Scholar 

  73. 73.

    Deng J, Pan J, Han X, Yu L, Chen J, Zhang W, et al. PDGFBB-modified stem cells from apical papilla and thermosensitive hydrogel scaffolds induced bone regeneration. Chem Biol Interact. 2020;316:108931.

    CAS  Article  PubMed  Google Scholar 

  74. 74.

    Wang X, Wang Y, Gou W, Lu Q, Peng J, Lu S. Role of mesenchymal stem cells in bone regeneration and fracture repair: a review. Int Orthop. 2013;37(12):2491–8.

    Article  PubMed  PubMed Central  Google Scholar 

  75. 75.

    Baxter MA, Wynn RF, Jowitt SN, Wraith JE, Fairbairn LJ, Bellantuono I. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells. 2004;22(5):675–82.

    CAS  Article  PubMed  Google Scholar 

  76. 76.

    Bonab MM, Alimoghaddam K, Talebian F, Ghaffari SH, Ghavamzadeh A, Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol. 2006;7(1):14.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  77. 77.

    Walters EM, Wells KD, Bryda EC, Schommer S, Prather RS. Swine models, genomic tools and services to enhance our understanding of human health and diseases. Lab Anim (NY). 2017;46(4):167–72.

    Article  Google Scholar 

Download references


Not applicable.


This work was supported by grants from the National Nature Science Foundation of China (NNSFC 81991504 and 81974149 to Y.L), the Beijing Baiqianwan Talents Project (2017A17 to Y.L), Beijing Peak Scheme Funding Support (DFL20181501 to Y.L), National High - level Talent Special Funding Support (to Y.L), and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX202121 to Y.L)

Author information




JF contributed to the conception, design, statistical analysis, and drafting of the manuscript. JF and YW performed the literature search and collected the data. JY and JD contributed to the methodology. JX and YL resolved any differences through discussions and supervised the study. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Junji Xu or Yi Liu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1.

(DOCX 18 kb)

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fu, J., Wang, Y., Jiang, Y. et al. Systemic therapy of MSCs in bone regeneration: a systematic review and meta-analysis. Stem Cell Res Ther 12, 377 (2021).

Download citation


  • Mesenchymal stem cells
  • Bone regeneration
  • Systemic treatment
  • Meta-analysis